Optimally Navigating the ‘Next Normal’ for Oncology Clinical Trials

Despite the many adaptations that have emerged over the course of 2020 and into 2021 to ensure oncology clinical trials are not disrupted, the number one challenge remains: adequate site selection.

Recent global events have created opportunities to reconfigure and transform how clinical trials operate. In doing so, it’s become very clear there is more than one way of doing things. There are a number of ‘next normal’ business considerations to be addressed as the industry moves forward into a post-COVID era.

Julie Martin, CEO & co-Owner of Scimega Research looks to the future and how to identify key operational process and adaptations to help US sponsors optimally navigate the ‘new normal’ in clinical trial operations in Canada and other geographic areas. In this webinar, Julie will share strategies for how to leverage lessons learned in 2020 and put these into action to maximize clinical development progress in 2021-22.

Register for this webinar to learn more about:

• Strategies used to mitigate threats in 2020 & 2021
• How to continue successfully navigating the transition period
• Cutting-edge small & mid-size oncology biotech trials: where to run them & decision factors for our choice of regions in 2021-2022

Bonus Offer: Register now and receive immediate access to the white paper Expert Guidance to Key Advantages of Canadian Regulatory Landscape.

Speaker

Julie Martin, M.Sc., MBA, Lean certified, CEO & co-Owner, Scimega

Julie has been part of the team at Scimega, since 2013. Her passion for the business stems from knowing its expert oncology clinical development services add distinct value to industry stakeholders at a time when it’s needed most. As CEO, Julie’s vision is to secure the company’s long-term success by leveraging her in-depth industry expertise & business acumen. She equates that success with setting a clear vision for the organization’s continued sense of purpose. Julie is responsible for developing successful business strategies & leveraging industry opportunities all of which support the common vision she shares with her team. Her leadership & collaboration with the managing Board of Directors, with whom Julie has worked alongside since 2013, ensure the business excellence upon which Scimega has built its reputation. Julie plays a vital role in promoting Scimega’s expertise and showcasing Canada’s attributes as a formidable partner in global oncology drug development.

Message Presenter